"I don't believe drug advertising is going to stall," Ramspacher says, "but we will see a greater amount spent on unbranded
disease awareness campaigns and corporate reputation ads. There will be a shift and redirection, as opposed to an elimination
or reduction, in promotional spending."
Diane West is a freelance writer covering healthcare and issues facing the pharmaceutical industry. She can be reached at firstname.lastname@example.org